FindTrial
Sign In

Nogapendekin Alfa

DRUG2 trials

Sponsors

SWOG Cancer Research Network, National Cancer Institute (NCI)

Conditions

Advanced Lung Non-Small Cell CarcinomaColorectal CarcinomaColorectal NeoplasmLynch SyndromeRecurrent Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8

Phase 2

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
Active, not recruitingNCT05096663
SWOG Cancer Research NetworkAdvanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIA Lung Cancer AJCC v8 +6
Start: 2022-03-15End: 2027-12-01Updated: 2026-05-18
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome
Active, not recruitingNCT05419011
National Cancer Institute (NCI)Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome
Start: 2023-05-08End: 2028-01-01Target: 186Updated: 2026-06-17

Related Papers

Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet)
Frontiers in Immunology2026-05-19
Lung-MAP S1800D: A phase II/III study of N-803 (ALT-803) plus pembrolizumab versus standard of care in participants with stage IV or recurrent non-small cell lung cancer (NSCLC) previously treated with anti-PD-1 or anti-PD-L1 therapy.
Journal of Clinical Oncology2024-06-012 citations
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors
Journal for ImmunoTherapy of Cancer2023-10-0122 citations